Phathom Gets Expanded FDA OK of Voquezna in Non-Erosive GERD
By Colin Kellaher
Phathom Pharmaceuticals has received the Food and Drug Administration's expanded approval of its acid-reflux drug Voquezna for the most common form of gastroesophageal reflux disease, or GERD.
Phathom on Thursday said the approval covers Voquezna for the relief of heartburn associated with non-erosive GERD in adults.
The Florham Park, N.J., biopharmaceutical company said about 45 million American adults suffer from non-erosive GERD, which is characterized by typical GERD symptoms such as heartburn and regurgitation but without esophageal erosion, with roughly 15 million treated with a prescription medicine annually.
The FDA late last year approved Voquezna to treat all severities of erosive esophagitis, also known as erosive GERD, and in combination with antibiotics for the eradication of Helicobacter pylori infection.
Shares of Phathom, which closed Wednesday at $12.11, were recently up 5% at $12.72 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 18, 2024 08:42 ET (12:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying